<DOC>
	<DOCNO>NCT01000441</DOCNO>
	<brief_summary>Approximately 30 % patient rheumatoid arthritis inadequate response anti-TNF ( primarily loss response ) , leave two alternative : rotation second anti-TNF change biologic , different mechanism action , abatacept , rituximab tocilizumab . No controlled trial compare two strategy face face . The present objective investigate issue whether one strategy could better efficacy pragmatic trial set current practice .</brief_summary>
	<brief_title>Rotation Change Biotherapy After First Anti-TNF Treatment Failure Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Active erosive rheumatoid arthritis DAS28 equal great 3.2 Inadequate response 1st antiTNF Stable treatment DMARDs , oral corticosteroid ( &lt; = 10 mg/day prednisone equivalent ) precede month Counterindication antiTNF , abatacept , rituximab tocilizumab Pregnancy Age &lt; 18 year Impossibility give inform consent Impossibility follow 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Rheumatoid arthritis inadequate response 1 anti-TNF</keyword>
</DOC>